Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group Review uri icon


MeSH Major

  • Brain Neoplasms
  • Clinical Trials as Topic
  • Glioblastoma


  • Glioblastoma is the most common primary brain malignancy and is associated with poor prognosis despite aggressive local and systemic therapy, which is related to a paucity of viable treatment options in both the newly diagnosed and recurrent settings. Even so, the rapidly increasing number of targeted therapies being evaluated in oncology clinical trials offers hope for the future. Given the broad range of possibilities for future trials, the Brain Malignancy Steering Committee convened a clinical trials planning meeting that was held at the Udvar-Hazy Center in Chantilly, Virginia, on September 19 and 20, 2013. This manuscript reports the deliberations leading up to the event from the Targeted Therapies Working Group and the results of the meeting.

publication date

  • January 2015



  • Review



  • eng

PubMed Central ID

  • PMC4288520

Digital Object Identifier (DOI)

  • 10.1093/neuonc/nou154

PubMed ID

  • 25165194

Additional Document Info

start page

  • 180

end page

  • 8


  • 17


  • 2